^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Astrocytoma |
| Drug: | Voranigo (vorasidenib) (IDH1 inhibitor, IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma
Published date:
08/06/2024
Excerpt:
Servier...FDA) has approved VORANIGO®, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.
Source:
Title:
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Published date:
05/25/2023
Excerpt:
Of the 331 pts: median age: 40.4 years (range, 16 to 71); KPS =100: 53.5%; histological subtype: oligodendroglioma: 172 and astrocytoma: 159...This is the first prospective, randomized phase 3 study of a targeted therapy in grade 2 mIDH glioma. VOR significantly improved PFS by BIRC compared with PBO with a manageable safety profile.
DOI:
10.1200/JCO.2023.41.17_suppl.LBA1
Trial ID:
